Parkinson’s diseaseReferences

Acknowledgements

This evidence summary was written by:

William B. Grant, Ph.D.
Sunlight, Nutrition, and Health Research Center (SUNARC)
P.O. Box 641603
San Francisco, CA 94164-1603, USA 
www.sunarc.org       
wbgrant@infionline.net

The summary was reviewed by:

Cedric Annweiler <ceannweiler@chu-angers.fr>
Marian L. Evatt <mevatt@emory.edu>

Complete bibliography of research used in this summary

We found a significant body of evidence when researching the role of vitamin D in Parkinson’s disease.  The research we have cited in our summary is listed below, with links to PubMed abstracts and full-text for those who wish to explore further.

1234567891011121314151617181920212223242526262727282930313233343536373839404142434445464748495051525354555657585960616263646566

Page last edited: 03 May 2011

References

  1. Anderson, C. Checkoway, H. Franklin, G. M. Beresford, S. Smith-Weller, T. Swanson, P. D. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord. 1999 Jan; 14 (1): 21-7.
  2. Anderson, R. F. Harris, T. A. Dopamine and uric acid act as antioxidants in the repair of DNA radicals: implications in Parkinson’s disease. Free Radic Res. 2003 Oct; 37 (10): 1131-6.
  3. Andreadou, E. Nikolaou, C. Gournaras, F. Rentzos, M. Boufidou, F. Tsoutsou, A. Zournas, C. Zissimopoulos, V. Vassilopoulos, D. Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg. 2009 Nov; 111 (9): 724-8.
  4. Annweiler, C. Schott, A. M. Berrut, G. Chauvire, V. Le Gall, D. Inzitari, M. Beauchet, O. Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010 Aug; 62 (3): 139-50.
  5. Ascherio, A. LeWitt, P. A. Xu, K. Eberly, S. Watts, A. Matson, W. R. Marras, C. Kieburtz, K. Rudolph, A. Bogdanov, M. B. Schwid, S. R. Tennis, M. Tanner, C. M. Beal, M. F. Lang, A. E. Oakes, D. Fahn, S. Shoulson, I. Schwarzschild, M. A. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009 Dec; 66 (12): 1460-8.
  6. Barnum, C. J. Tansey, M. G. Modeling neuroinflammatory pathogenesis of Parkinson’s disease. Prog Brain Res. 2010; 184113-32.
  7. Betemps, E. J. Buncher, C. R. Birthplace as a risk factor in motor neurone disease and Parkinson’s disease. Int J Epidemiol. 1993 Oct; 22 (5): 898-904.
  8. Cekic, M. Cutler, S. M. Vanlandingham, J. W. Stein, D. G. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol Aging. 2009 May 29;
  9. Chen, H. Mosley, T. H. Alonso, A. Huang, X. Plasma urate and Parkinson’s disease in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol. 2009 May 1; 169 (9): 1064-9.
  10. Chen, H. O’Reilly, E. McCullough, M. L. Rodriguez, C. Schwarzschild, M. A. Calle, E. E. Thun, M. J. Ascherio, A. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol. 2007 May 1; 165 (9): 998-1006.
  11. Chen, H. Zhang, S. M. Hernan, M. A. Willett, W. C. Ascherio, A. Diet and Parkinson’s disease: a potential role of dairy products in men. Ann Neurol. 2002 Dec; 52 (6): 793-801.
  12. Choi, H. K. Liu, S. Curhan, G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005 Jan; 52 (1): 283-9.
  13. Dahodwala, N. Siderowf, A. Xie, M. Noll, E. Stern, M. Mandell, D. S. Racial differences in the diagnosis of Parkinson’s disease. Mov Disord. 2009 Jun 15; 24 (8): 1200-5.
  14. Dalbeth, N. Wong, S. Gamble, G. D. Horne, A. Mason, B. Pool, B. Fairbanks, L. McQueen, F. M. Cornish, J. Reid, I. R. Palmano, K. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis. 2010 Sep; 69 (9): 1677-82.
  15. Derex, L. Trouillas, P. Reversible parkinsonism, hypophosphoremia, and hypocalcemia under vitamin D therapy. Mov Disord. 1997 Jul; 12 (4): 612-3.
  16. Driver, J. A. Smith, A. Buring, J. E. Gaziano, J. M. Kurth, T. Logroscino, G. Prospective cohort study of type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2008 Oct; 31 (10): 2003-5.
  17. Ebadi, M. Sharma, S. K. Ghafourifar, P. Brown-Borg, H. El Refaey, H. Peroxynitrite in the pathogenesis of Parkinson’s disease and the neuroprotective role of metallothioneins. Methods Enzymol. 2005; 396276-98.
  18. Evatt, M. L. Beyond vitamin status: is there a role for vitamin d in Parkinson disease?. Arch Neurol. 2010 Jul; 67 (7): 795-7.
  19. Evatt, M. L. Delong, M. R. Khazai, N. Rosen, A. Triche, S. Tangpricha, V. Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008 Oct; 65 (10): 1348-52.
  20. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005 Jan; 29 (1): 21-30.
  21. Fernandes de Abreu, D. A. Eyles, D. Feron, F. Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology. 2009 Jun 20;
  22. Gao, X. Chen, H. Choi, H. K. Curhan, G. Schwarzschild, M. A. Ascherio, A. Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol. 2008 Apr 1; 167 (7): 831-8.
  23. Gao, X. Chen, H. Fung, T. T. Logroscino, G. Schwarzschild, M. A. Hu, F. B. Ascherio, A. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr. 2007 Nov; 86 (5): 1486-94.
  24. Gao, X. Simon, K. C. Han, J. Schwarzschild, M. A. Ascherio, A. Family history of melanoma and Parkinson disease risk. Neurology. 2009 Oct 20; 73 (16): 1286-91.
  25. Ghadirian, P. Shatenstein, B. Verdy, M. Hamet, P. The influence of dairy products on plasma uric acid in women. Eur J Epidemiol. 1995 Jun; 11 (3): 275-81.
  26. Grant, W. B. Dietary links to Alzheimer’s disease. Alz Dis Rev. 1997; 242-55.
  27. Hernan, M. A. Takkouche, B. Caamano-Isorna, F. Gestal-Otero, J. J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002 Sep; 52 (3): 276-84.
  28. Hirtz, D. Thurman, D. J. Gwinn-Hardy, K. Mohamed, M. Chaudhuri, A. R. Zalutsky, R. How common are the “common” neurologic disorders?. Neurology. 2007 Jan 30; 68 (5): 326-37.
  29. Hofman, A. Collette, H. J. Bartelds, A. I. Incidence and risk factors of Parkinson’s disease in The Netherlands. Neuroepidemiology. 1989; 8 (6): 296-9.
  30. Holmoy, T. Moen, S. M. Assessing vitamin D in the central nervous system. Acta Neurol Scand Suppl. 2010; (190): 88-92.
  31. Hu, G. Jousilahti, P. Bidel, S. Antikainen, R. Tuomilehto, J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007 Apr; 30 (4): 842-7.
  32. Invernizzi, M. Carda, S. Viscontini, G. S. Cisari, C. Osteoporosis in Parkinson’s disease. Parkinsonism Relat Disord. 2009 Jun; 15 (5): 339-46.
  33. Jankovic, J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr; 79 (4): 368-76.
  34. Jomova, K. Vondrakova, D. Lawson, M. Valko, M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010 Aug 22;
  35. Kenborg, L. Lassen, C. F. Ritz, B. Schernhammer, E. S. Hansen, J. Gatto, N. M. Olsen, J. H. Outdoor work and risk for Parkinson’s disease: a population-based case-control study. Occup Environ Med. 2010 Sep 30;
  36. Kim, J. S. Kim, Y. I. Song, C. Yoon, I. Park, J. W. Choi, Y. B. Kim, H. T. Lee, K. S. Association of vitamin D receptor gene polymorphism and Parkinson’s disease in Koreans. J Korean Med Sci. 2005 Jun; 20 (3): 495-8.
  37. Knekt, P. Kilkkinen, A. Rissanen, H. Marniemi, J. Saaksjarvi, K. Heliovaara, M. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010 Jul; 67 (7): 808-11.
  38. Kones, R. Parkinson’s disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutr Clin Pract. 2010 Aug; 25 (4): 371-89.
  39. Kuhn, D. M. Sakowski, S. A. Sadidi, M. Geddes, T. J. Nitrotyrosine as a marker for peroxynitrite-induced neurotoxicity: the beginning or the end of the end of dopamine neurons?. J Neurochem. 2004 May; 89 (3): 529-36.
  40. Kurtzke, J. F. Goldberg, I. D. Parkinsonism death rates by race, sex, and geography. Neurology. 1988 Oct; 38 (10): 1558-61.
  41. Kutzing, M. K. Firestein, B. L. Altered uric acid levels and disease states. J Pharmacol Exp Ther. 2008 Jan; 324 (1): 1-7.
  42. Lorefalt, B. Toss, G. Granerus, A. K. Bone mass in elderly patients with Parkinson’s disease. Acta Neurol Scand. 2007 Oct; 116 (4): 248-54.
  43. Lux, W. E. Kurtzke, J. F. Is Parkinson’s disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology. 1987 Mar; 37 (3): 467-71.
  44. Newmark, H. L. Newmark, J. Vitamin D and Parkinson’s disease–a hypothesis. Mov Disord. 2007 Mar 15; 22 (4): 461-8.
  45. Noonan, C. W. Reif, J. S. Yost, M. Touchstone, J. Occupational exposure to magnetic fields in case-referent studies of neurodegenerative diseases. Scand J Work Environ Health. 2002 Feb; 28 (1): 42-8.
  46. Pacher, P. Beckman, J. S. Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan; 87 (1): 315-424.
  47. Park, J. Yoo, C. I. Sim, C. S. Kim, H. K. Kim, J. W. Jeon, B. S. Kim, K. R. Bang, O. Y. Lee, W. Y. Yi, Y. Jung, K. Y. Chung, S. E. Kim, Y. Occupations and Parkinson’s disease: a multi-center case-control study in South Korea. Neurotoxicology. 2005 Jan; 26 (1): 99-105.
  48. Park, M. Ross, G. W. Petrovitch, H. White, L. R. Masaki, K. H. Nelson, J. S. Tanner, C. M. Curb, J. D. Blanchette, P. L. Abbott, R. D. Consumption of milk and calcium in midlife and the future risk of Parkinson disease. Neurology. 2005 Mar 22; 64 (6): 1047-51.
  49. Sanchez, B. Relova, J. L. Gallego, R. Ben-Batalla, I. Perez-Fernandez, R. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum. J Neurosci Res. 2009 Feb 15; 87 (3): 723-32.
  50. Sato, Y. Honda, Y. Iwamoto, J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology. 2007 Mar 20; 68 (12): 911-5.
  51. Sato, Y. Honda, Y. Iwamoto, J. Kanoko, T. Satoh, K. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord. 2005 Dec; 20 (12): 1598-603.
  52. Sato, Y. Iwamoto, J. Kanoko, T. Satoh, K. Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2006 Jul; 21 (7): 924-9.
  53. Sato, Y. Kaji, M. Tsuru, T. Satoh, K. Kondo, I. Vitamin K deficiency and osteopenia in vitamin D-deficient elderly women with Parkinson’s disease. Arch Phys Med Rehabil. 2002 Jan; 83 (1): 86-91.
  54. Sato, Y. Kikuyama, M. Oizumi, K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology. 1997 Nov; 49 (5): 1273-8.
  55. Sato, Y. Manabe, S. Kuno, H. Oizumi, K. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999 Jan; 66 (1): 64-8.
  56. Schlesinger, I. Schlesinger, N. Uric acid in Parkinson’s disease. Mov Disord. 2008 Sep 15; 23 (12): 1653-7.
  57. Schwartz, G. G. Multiple sclerosis and prostate cancer: what do their similar geographies suggest?. Neuroepidemiology. 1992; 11 (4-6): 244-54.
  58. Schwarzschild, M. A. Schwid, S. R. Marek, K. Watts, A. Lang, A. E. Oakes, D. Shoulson, I. Ascherio, A. Hyson, C. Gorbold, E. Rudolph, A. Kieburtz, K. Fahn, S. Gauger, L. Goetz, C. Seibyl, J. Forrest, M. Ondrasik, J. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65 (6): 716-23.
  59. Smith, M. P. Fletcher-Turner, A. Yurek, D. M. Cass, W. A. Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine. Neurochem Res. 2006 Apr; 31 (4): 533-9.
  60. Surmeier, D. J. Guzman, J. N. Sanchez-Padilla, J. Goldberg, J. A. What causes the death of dopaminergic neurons in Parkinson’s disease?. Prog Brain Res. 2010; 18359-77.
  61. Tüchsen, F. Jensen, A. A. Agricultural work and the risk of Parkinson’s disease in Denmark, 1981-1993. Scand J Work Environ Health. 2000 Aug.; 26 (4): 359-62.
  62. Tuohimaa, P. Keisala, T. Minasyan, A. Cachat, J. Kalueff, A. Vitamin D, nervous system and aging. Psychoneuroendocrinology. 2009 Dec; 34 Suppl 1S278-86.
  63. van der Veen, R. C. Hinton, D. R. Incardonna, F. Hofman, F. M. Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J Neuroimmunol. 1997 Jul; 77 (1): 1-7.
  64. Wang, J. Y. Wu, J. N. Cherng, T. L. Hoffer, B. J. Chen, H. H. Borlongan, C. V. Wang, Y. Vitamin D(3) attenuates 6-hydroxydopamine-induced neurotoxicity in rats. Brain Res. 2001 Jun 15; 904 (1): 67-75.
  65. Weisskopf, M. G. O’Reilly, E. Chen, H. Schwarzschild, M. A. Ascherio, A. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol. 2007 Sep 1; 166 (5): 561-7.
  66. Yanagihara, R. Garruto, R. M. Gajdusek, D. C. Tomita, A. Uchikawa, T. Konagaya, Y. Chen, K. M. Sobue, I. Plato, C. C. Gibbs, C. J., Jr. Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol. 1984 Jan; 15 (1): 42-8.